Navigation Links
VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD
Date:7/1/2009

Hollywood, FL July 1, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD). VYVANSE is the first approved stimulant for adults with ADHD to be evaluated in this setting, and these data were presented today at the 49th annual New Clinical Drug Evaluation Unit meeting in Hollywood, FL. VYVANSE is currently approved by the US Food and Drug Administration (FDA) for the treatment of ADHD in children age 6 to 12 years and in adults with ADHD.

"Long-acting medication may be important for adults with ADHD because ADHD symptoms, such as inattention, hyperactivity, and impulsivity, may impact them at work, as well as in at least one other area of their life," said Matthew Brams, MD, study author and psychiatrist in private practice with Bayou City Research, Ltd in Houston. "In this study, adults taking VYVANSE demonstrated significant efficacy as measured by the Permanent Product Measure of Performance (PERMP), from two hours, the first time point measured, up to 14 hours following administration. Additionally, adults taking VYVANSE demonstrated significant ADHD symptom improvement, as measured by the ADHD Rating Scale (ADHD-RS) with adult prompts. These findings may be important for adults who require ADHD symptom management at work, at home, and in social settings."

In this study, investigators evaluated adults with ADHD in an adult simulated workplace environment setting. In this setting, adults engaged in tests and activities that require a level of attention needed in many workplace settings. The efficacy of VYVANSE was measured by PERMP, a validated, time sensitive, skill adjusted math test designed to evaluate an adult's ability t
'/>"/>

Contact: Matthew Cabrey (Shire North America)
484-595-8248
Porter Novelli
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
2. VYVANSE provided behavior, inattention and math test score improvements in children with ADHD
3. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
4. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
5. FDA approves additional dosage strengths of Vyvanse
6. Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
7. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
8. Record Number of Volunteers Provided Free Dental Care to Needy Children in Minnesota
9. Chronic Pain Patients Now Have Hope With Carryover Pain Relief Provided By Repeated Interferential Treatments
10. National Institutes of Health Expands Use of Emergency Notification Services Provided by Send Word Now(TM) Across NIH Campus
11. $5.15 Million Provided to Support Local Health Care Needs
Post Your Comments:
*Name:
*Comment:
*Email: